



Real World Testing Results Report 2024

11407 Wistful Vista, Porter Ranch, CA, 91326-4182
Telephone: 310.752.7772
Email: support@geniusdoc.com

TABLE OF CONTENTS

1.	GENERAL INFORMATION	2
2.	CHANGES TO ORIGINAL PLAN	2
3.	SUMMARY OF TESTING METHODS AND KEY FINDINGS	3
4.	STANDARDS UPDATES (INCLUDING SVAP AND USCDI)	3
5.	CARE SETTINGS	4
6.	METRICS AND OUTCOMES.....	5
7.	KEY MILESTONES	10
8.	ATTESTATION	10

1. GENERAL INFORMATION

Report ID Number	20231116ged
Developer Name	GeniusDoc, Inc.
Product Name(s)	GeniusDoc
Version Number(s)	12.0
Certified Health IT Product List (CHPL) ID(s)	15.02.05.1529.GDOC.01.01.1.211209
Developer Real World Testing PLAN Page URL	https://www.geniusdoc.com/RealWorldTesting.php
Developer Real World Testing RESULTS Page URL	https://www.geniusdoc.com/RealWorldTesting.php

2. CHANGES TO ORIGINAL PLAN

Summary of Change	Reason	Impact
The data collection period given in the test plan was from May to July 2024. We modified our data collection to occur over the year.	We modified the data collection period so that we could monitor the data and ensure that by the end of the year, we were able to demonstrate the real world capabilities of our product.	This change allowed us to show the real world capabilities of our product. We worked with our users to use our product features that were underutilized.
Tested C1, C2 and C3 measures using CYPRESS test tool instead of the production environment.	All our clients use MIPS CQM measures for reporting MIPS Quality data. eCQM measures were not used by any of our clients in this testing period.	While eCQM data is not generated in production environment, but the data is generated and validated successfully in test environment.
Tested F2, F4, and F5 measures using the NIST test tool instead of the production environment.	The production testing partner was unavailable to test the transmission to public health agencies.	The testing with a live registry was not available, but the transmission and validity of messages were successfully confirmed.

3. SUMMARY OF TESTING METHODS AND KEY FINDINGS

The care settings used by GeniusDoc EHR for Real World testing were Oncology, Rheumatology, and Pulmonary. Most of the Real World testing scenarios are tested on these specialties to demonstrate the success of interoperability criteria.

The certified criteria are available to all the providers from the start of the year and users could utilize them per their needs. Also, the training is provided to the users.

The logs are verified to determine how often providers use the functions of Real World testing. The findings are mixed as some of the criteria are heavily used and others are not used at all. The criteria which are low in number may require further training and facilitation to providers for the adoption of certified criteria.

4. STANDARDS UPDATES (INCLUDING SVAP AND USCDI)

Both required and voluntary standards updates must be addressed in the Real-World Testing plan. Real World Testing plans must include all certified health IT updated to newer versions of standards prior to August 31 of the year in which the updates were made. Indicate as to whether optional standards, via SVAP and/or USCDI, are leveraged as part of the certification of your health IT product(s).

- Yes, I have products certified with voluntary SVAP or USCDI standards. (If yes, please complete the table below).

- No, none of my products include these voluntary standards.

USCDI Standards	
Standard (and version)	USCDI V1
Updated certification criteria and associated product	b(1), b(2), e(1), f(5), g(9)
CHPL Product Number	15.02.05.1529.GDOC.01.01.1.211209
Method used for standard update	Cures Update
Date of ONC ACB notification	12/12/2022
Date of customer notification (SVAP only)	N/A
Conformance measure	§ 170.315(b)(1) Transitions of care § 170.315(b)(2) Clinical information reconciliation and incorporation § 170.315(e)(1) View, download, and transmit to 3rd party § 170.315(f)(5) Transmission to public healthagencies — electronic case reporting § 170.315(g)(9) Application access— all data request
USCDI updated certification criteria (and USCDI version)	b(1), b(2), e(1), f(5), g(9) — USCDI V1

5. CARE SETTINGS

The care settings which were tested are:

- Oncology
- Rheumatology
- Pulmonary

Note: The product functionality is common for all other specialties as well.

6. METRICS AND OUTCOMES

Measurement /Metric	Associated Criterion(a)	Relied Upon Software (if applicable)	Outcomes	Challenges Encountered (if applicable)
Care Coordination	170.315(B)(1) Transitions of Care 170.315(B)(2) Clinical Information Reconciliation and Incorporation 170.315(H)(1) Direct Project	SureScripts	The Total number of CCDAs files sent out electronically is 7. 100% successfully received by HISP. C-CDAs are evaluated with C-CDA validator tool and are conformant. More than 75% of trading partner's TOC C-CDAs were successfully received by GeniusDoc. The total count of successful reconciliation of problems, medications, and medication allergies is 5.	
Care Coordination – eRx	170.315(B)(3) Electronic Prescribing	SureScripts, Best Sync	The total no. of prescriptions sent out electronically is 13802. More than 90% of prescriptions are documented and sent electronically.	

			More than 95% of prescriptions are received by pharmacies.	
Clinical Quality Measures	<p>170.315(C)(1) Clinical Quality Measures (CQMS) - Record and Export</p> <p>170.315(C)(2) Clinical Quality Measures (CQMS) - Import and Calculate</p> <p>170.315(C)(3) Clinical Quality Measures (CQMS) - Report</p>		<p>All our clients use MIPS CQM measures for reporting MIPS Quality data.</p> <p>eCQM measures were not used by any of our clients in this testing period.</p>	<p>Since this feature is not used by our clients, we have tested the functionality successfully on our test environment (copy of live environment).</p> <p>A total of 7 QRDA I and QRDA III files were generated. GeniusDoc imported the files into a test account and generated QRDA I and QRDA III.</p> <p>These results were compared and validated with 100% accuracy and 0 errors.</p>
Patient Engagement	170.315(E)(1) View, Download and Transmit to 3rd Party		The total number of patients who log into their patient portal to view, download, or transmit their health data is 14166. More than 90% of unique patients were provided with timely access to	

			their health information.	
Public Health- Immunization Registries	170.315(F)(1) Transmission to Immunization Registries		<p>The total count of successful transmission of Immunizations to registry is 29. Visual validation confirmed that 100% of immunization records were posted successfully and received an ACK.</p> <p>There is no client usage for the download of Immunization history.</p>	
Public Health- Syndromic Surveillance	170.315(F)(2) Transmission to Public Health Agencies – Syndromic Surveillance		<p>There was no client utilization for this measure in this testing period.</p>	<p>Since this feature is not used by our clients, we have tested the functionality successfully on our test environment (Copy of Live Environment). A total of 6 patient logs were recorded.</p> <p>100% of Syndromic Surveillance messages successfully submitted and acknowledged in the NIST test tool. Validated by visual inspection.</p>

<p>Public Health- Cancer registries</p>	<p>170.315(f)(4) Transmission to Cancer Registries</p>		<p>There was no client utilization for this measure in this testing period.</p>	<p>Since this feature is not used by our clients, we have tested the functionality successfully on our test environment (Copy of Live Environment). A total of 5 patient logs were recorded.</p> <p>100% of Cancer Care information messages successfully submitted and acknowledged in the NIST test tool. Validated by visual inspection.</p>
<p>Public Health- Electronic Case reporting</p>	<p>170.315(f)(5) Transmission to public health agencies — Electronic Case reporting</p>		<p>There was no client utilization for this measure in this testing period.</p>	<p>Since this feature is not used by our clients, we have tested the functionality successfully on our test environment (Copy of Live Environment). A total of 8 patient logs were recorded.</p> <p>100% of electronic case reporting messages successfully submitted and</p>

				<p>acknowledged in the NIST test tool.</p> <p>Validated by visual inspection.</p>
<p>Application Programming Interfaces</p>	<p>170.315(G)(7) Application Access - Patient Selection</p> <p>170.315(G)(9) Application Access- All Data Request</p> <p>170.315(g)(10) Standardized API for patient and population services</p>		<p>There are no active API Interfaces.</p> <p>This measure applies to all our targeted practice settings as the API capabilities work the same for all sites.</p>	<p>Since this feature is not used by our clients, we have tested this capability in the live system by creating test patients. A total of 54 transaction logs were recorded while the users tried to perform patient selection and other data requests.</p> <p>Users were able to retrieve 100% of encounters from FHIR API data and it matches with the EHR. Confirmed by visual validation of the resources below.</p> <ul style="list-style-type: none"> a. Demographics b. Problems C. Medications d. Allergies

7. KEY MILESTONES

Key Milestone	Care Setting	Date/Timeframe
Real World Test Plan preparation and submission.	Oncology, Rheumatology, and Pulmonary	October 25, 2023
Begin collection of information for all the care settings.	Oncology, Rheumatology, and Pulmonary	January 1, 2024
End of Real World Testing period – Final collection of all data for analysis for all care settings.	Oncology, Rheumatology, and Pulmonary	January 1, 2025
Final analysis and report creation	Oncology, Rheumatology, and Pulmonary	February 5, 2025
Submission of Real World Testing report.	Oncology, Rheumatology, and Pulmonary	February 7, 2025

8. ATTESTATION

This Real-World Testing results report is complete with all required elements, including. measures that address all certification criteria and care settings. All information in this results report is up to date and fully addresses the health IT developer’s Real World Testing requirements.

Authorized Representative Name: Bosco

Authorized Representative Email: bosco@geniusdoc.com

Authorized Representative Phone: (310) 752-7772

Authorized Representative Signature:



Date: 02/07/2025